Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05106127
Study type Interventional
Source Evergreen Therapeutics, Inc.
Contact Xin Du, Ph.D.
Phone 2404064016
Email david.du@egpharm.com
Status Not yet recruiting
Phase Phase 2
Start date March 2025
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04574284 - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer Phase 2
Withdrawn NCT06046274 - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Phase 2
Recruiting NCT05112991 - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer Phase 2
Completed NCT01289041 - BKM120 as Second-line Therapy for Advanced Endometrial Cancer Phase 2
Not yet recruiting NCT05077215 - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer Phase 3
Recruiting NCT05481645 - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. Phase 2